Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit?

Abstract

With increasing adoption of transoral robotic surgery (TORS) for oropharyngeal cancer (OPC), more patients may receive trimodality therapy. We sought to investigate outcomes and toxicities in this cohort.